40–80 mg/day of isoflavones; the effect may depend on equol production.
Frequency −20 to −34 %, intensity −26 % — takes weeks
View the study (meta-analysis) →⏱ 4 min read
Isoflavones are a family of polyphenols found in especially concentrated amounts in soy (Glycine max), where the three main ones are genistein, daidzein, and glycitein; chemically they are phytoestrogens, that is, plant-derived compounds with some ability to bind to human estrogen receptors (especially estrogen receptor beta, with lower affinity for alpha), a property that produces mild estrogenic or antiestrogenic effects depending on the underlying hormonal context, a peculiar pharmacological characteristic that underlies most of their clinical indications in menopausal symptoms, bone health, cardiovascular health, and, with heterogeneous data, cancer prevention.
A fundamental aspect for understanding the clinical variability observed with isoflavones is the individual metabolism of daidzein to equol, its intestinal metabolite with significantly higher estrogenic affinity: only a proportion of people (50-70 percent of Asians who habitually consume soy, 25-30 percent of Westerners on low-soy diets) have a gut microbiota with the enzymatic capacity to produce equol, and it is these people who appear to obtain the greatest clinical benefits; people who do not produce equol obtain quantitatively smaller effects, a probable explanation for the heterogeneous results between studies and between populations.
The most extensively studied indication with clinical support is the reduction of hot flashes and night sweats in postmenopausal women: several meta-analyses have documented modest but significant reductions in the frequency and severity of hot flashes with supplementation at 40-120 milligrams daily of isoflavones for 12-24 weeks, with effect sizes quantitatively smaller than those of estrogen hormone replacement therapy but clinically relevant and with a much more favorable safety profile for women with contraindications to pharmaceutical hormones.
The effects are more consistent in equol-producing women, and specific oral S-equol preparations (S-equol, available as a medicine in some Asian countries) show more consistent effects than conventional isoflavones in women who are not endogenous producers.
In postmenopausal osteoporosis, several trials have documented modest improvements in biochemical bone markers and slight reductions in bone mineral density loss with high-dose supplementation for 12-24 months; the effects are quantitatively smaller than those of bisphosphonates or pharmaceutical estrogens but may have a place as a complement or as an option for women with contraindications to standard pharmacological interventions.
On the lipid profile, soy proteins with isoflavones modestly reduce LDL cholesterol (typically 4-8 percent) with sustained intake through diet or supplementation; the population-level cardiovascular effects associated with regular consumption of soy products (traditional in Asian diets) are partly attributed to this lipid modulation and to other nutritional components of soy.
The relationship between isoflavones and breast cancer is one of the most studied and most nuanced topics in clinical nutrition: epidemiological data associate sustained dietary consumption of soy from an early age with a lower risk of breast cancer (especially in Asian populations with traditional consumption since childhood), but high-dose supplementation started in adulthood is more controversial; the reasonable current clinical position is that habitual dietary consumption of soy products is safe and possibly beneficial, whereas high-dose supplementation in women with active or recent hormone-dependent breast cancer should be evaluated case by case with their oncologist.
The doses studied as a supplement range from 40 to 120 milligrams daily of total isoflavones (typically expressed as aglycones, with variable ratios of genistein, daidzein, and glycitein depending on the product), divided into one or two doses; habitual dietary consumption of traditional soy products (tofu, tempeh, miso, soy milk, edamame) provides modest but cumulative amounts with real population-level effects; fermented products (tempeh, miso, natto) have superior bioavailability because partial bacterial activity has already hydrolyzed some isoflavones to their active forms.
Generally well tolerated; the adverse effects described are rare and mild (mild digestive discomfort, occasionally headache or skin erythema); people with active or recent hormone-dependent breast cancer, with a strong family history of hormone-dependent cancer, or with estrogen receptor-positive status in a previous tumor should consult their oncologist before starting supplementation with concentrated isoflavones; those taking tamoxifen (adjuvant treatment for breast cancer) are in a particularly complex situation with heterogeneous data on pharmacodynamic interaction; those taking levothyroxine may have mild interference with absorption (separate the doses by at least 4 hours); people with soy allergy should avoid them entirely; in pregnancy, habitual dietary consumption is safe, but high supplement doses during pregnancy and breastfeeding are discouraged as a precaution; in children, consumption of soy products is generally safe, although sustained exposure to high doses from infant formula has been a subject of debate in some contexts.
Information, not medical advice. Scientific evidence reflects the quality of the studies.